Aduhelm reignites questions around ties between pharma and patient advocacy orgs
In the latest round of patient advocacy and the FDA, the drug reviewer approved Biogen and Eisai’s Alzheimer’s disease med Aduhelm over the advice of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
